Strategic partnerships Hepregen already collaborates with over 20 pharmaceutical companies using the HepatoPac platform, indicating a proven interest from the market and multiple entry points for expanded or renewed partnerships, licensing, or co-development arrangements.

Targeted drug safety The HepatoPac system offers a more predictive liver model for toxicity screening and preclinical DMPK/safety, presenting opportunities to position Hepregen as a preferred supplier for early-stage safety assessments in pharmaceutical pipelines.

Microphysiological edge With its MPCC-based liver model that maintains in vivo-like liver functions for weeks, Hepregen can differentiate from competitors through higher predictive value, enabling upsell to higher-tier service packages or expanded testing menus.

Small team agility As a 2–10 employee company with established funding and revenue, there is potential for quick decision cycles, targeted outbound selling to decision-makers at pharma companies, and scalable pilot programs to demonstrate ROI with HepatoPac.

Expansion opportunities Commercial avenues exist in efficacy studies, biomarker discovery, diseased liver models, and stem cell applications, offering cross-sell and up-sell possibilities to existing pharma partners and new clients seeking liver-specific translational insights.